$NGNE Cashflow Statement | Understand Stock

$NGNE

$26.99 +$3.45 (14.66%) Close

$NGNE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Bargain purchase gain in connection with reverse merger
Depreciation and amortization of property and equipment
Amortization of operating lease right-of-use assets
Asset impairment
Non-cash operating lease expense
Amortization of finance lease right-of-use assets
Amortization and accretion of premiums/discounts on held-to-maturity investments
Loss on disposal of property and equipment
Write-off of right-of-use asset upon lease termination
Change in contingent value rights liability
Gain on lease modification
Changes in assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable and accrued liabilities
Operating lease right-of-use assets
Accounts payable
Accrued expenses and other liabilities
Operating lease liabilities

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Purchase of available-for-sale securities
Proceeds from maturities of available-for-sale securities
Cash and restricted cash acquired from reverse merger transaction
Reverse merger transaction costs paid
Purchases of held-to-maturity investments
Proceeds from maturities of held-to-maturity investments
Net cash provided by (used in) investing activities

Financing activities
Payment of deferred offering costs related to at-the-market sales agreement
Proceeds from issuance of Series B convertible preferred stock, net of offering costs paid
Offering costs in connection with pre-closing financing
Transaction costs related to reverse merger
Proceeds from the issuance of common stock upon exercise of options
Proceeds from private financing, net of offering costs paid
Principal payments on finance leases
Proceeds from the issuance of common stock under Employee Stock Purchase Plan
Net cash provided by financing activities
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of non-cash investing and financing activities:
Additions to operating lease right of use assets from new operating lease liabilities
Property and equipment included in accounts payable and accrued expenses
Additions to finance lease right of use assets from new finance lease liabilities
Offering costs related to private offering, included in accounts payable and accrued expenses
Operating lease liabilities assumed in connection with the reverse merger
Contingent consideration liability assumed in the reverse merger
Other liabilities assumed in the reverse merger
Assets acquired in the reverse merger including $53.9 million in ST investments and $0.8 million in other monetary assets
Issuance of common stock and pre-funded warrants to former stockholders of Neoleukin Therapeutics, Inc. in connection with the reverse merger
Offering costs in connection with pre-closing financing included in accounts payable and accrued expenses
Transaction costs related to reverse merger included in accounts payable and accrued expenses
Conversion of preferred stock into common stock in connection with reverse merger
Supplemental cash flow information:
Cash paid for interest
Deferred offering costs reclassified to additional paid-in capital

Comments